Pulmonary predictors of survival in amyotrophic lateral sclerosis: Use in clinical trial design

被引:60
|
作者
Schmidt, EP
Drachman, DB
Wiener, CM
Clawson, L
Kimball, R
Lechtzin, N
机构
[1] Dept Med, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
关键词
amyotrophic lateral sclerosis; prognosis; pulmonary function; spirometry; therapeutic trial design;
D O I
10.1002/mus.20450
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The rapidity of progression of amyotrophic lateral sclerosis (ALS) to death or respiratory failure impacts patients, clinicians, and clinical investigators. This study compared the abilities of various pulmonary function tests to predict tracheostomy-free survival. We evaluated 95 ALS patients by determining upright and supine forced vital capacity (FVC), maximal inspiratory (MIP) and expiratory (MEP) pressures, arterial partial pressure of carbon dioxide (PaCO2), and transdiaphragmatic sniff pressures (Pdi-sniff). Tracheostomy-free survival time was measured from the date of spirometry. Supine FVC, upright FVC, MIP, MEP, and Pdi-sniff were significantly associated with tracheostomy-free survival after controlling for non-pulmonary factors, whereas PaCO2 was not. A normal supine FVC, MIP, or MEP was highly predictive for one-year survival. These tests are well suited to predict survival for trial enrollment and patient counseling. Supine FVC's simplicity of use and availability to ALS investigators makes it a particularly attractive predictor of one-year survival in ALS.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 50 条
  • [1] Pulmonary Function Variables as Predictors of Survival in Patients with Amyotrophic Lateral Sclerosis
    Cheng, G.
    Bach, J. R.
    EUROPEAN NEUROLOGY, 2009, 61 (05) : 319 - 319
  • [2] Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
    Fournier, Christina N.
    NEUROTHERAPEUTICS, 2022, 19 (04) : 1180 - 1192
  • [3] Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
    Christina N. Fournier
    Neurotherapeutics, 2022, 19 : 1180 - 1192
  • [4] Amyotrophic lateral sclerosis: early predictors of prolonged survival
    Adam Czaplinski
    Albert A. Yen
    Stanley H. Appel
    Journal of Neurology, 2006, 253 : 1428 - 1436
  • [5] Amyotrophic lateral sclerosis: Early predictors of prolonged survival
    Czaplinski, A
    Yen, AA
    Appel, SH
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S208 - S208
  • [6] The predictors of survival in Chinese amyotrophic lateral sclerosis patients
    Wei, Qianqian
    Chen, Xueping
    Zheng, Zhenzhen
    Guo, Xiaoyan
    Huang, Rui
    Cao, Bei
    Zeng, Yan
    Shang, Huifang
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2015, 16 (3-4) : 237 - 244
  • [7] Disease progression in amyotrophic lateral sclerosis: Predictors of survival
    Magnus, T
    Beck, M
    Giess, R
    Puls, I
    Naumann, M
    Toyka, KV
    MUSCLE & NERVE, 2002, 25 (05) : 709 - 714
  • [8] Amyotrophic lateral sclerosis: early predictors of prolonged survival
    Czaplinski, Adam
    Yen, Albert A.
    Appel, Stanley H.
    JOURNAL OF NEUROLOGY, 2006, 253 (11) : 1428 - 1436
  • [9] ISSUES IN AMYOTROPHIC-LATERAL-SCLEROSIS CLINICAL-TRIAL DESIGN
    MUNSAT, TL
    PATHOGENESIS AND THERAPY OF AMYOTROPHIC LATERAL SCLEROSIS, 1995, 68 : 209 - 218
  • [10] A clinical trial of verapamil in amyotrophic lateral sclerosis
    Miller, RG
    Smith, SA
    Murphy, JR
    Brinkmann, JR
    Graves, J
    Mendoza, M
    Sands, ML
    Ringel, SP
    MUSCLE & NERVE, 1996, 19 (04) : 511 - 515